[Non-Hodgkin's lymphomas in childhood. Evaluation of therapeutic results according to histopathologic criteria (Catalan Interhospital Group of Pediatric Oncology)].
The results obtained in the treatment of 37 children with non Hodgkin lymphoma belonging to GICOP between january 1982 and december 1986 are analysed. The therapy depend on the anatomopathology following the working formulation; LSALL2 protocol is used in lymphoblastic lymphoma, Burkitt-82 in undifferentiated Burkitt lymphoma and COMP in the remaining complete remission was archived in 94.6%. Murphy's classification is used. Disease free survival is 81% at 30 months. The actuarial survival is 0.81 for LL and 0.84 for BK at 48 months. The results obtained in the treatment of Burkitt's lymphoma with Burkitt-82 protocol and specially the absence of CNS infiltration are remarkable.
Cubells Riero
J
J
Servicio de Pediatría, Hospital Sant Pau, Barcelona.
Pardo García
N
N
Turmo Martí
J
J
Vela Ferrer
E
E
Badía Torroella
R M
RM
González Rivero
M A
MA
Illa Sala
J
J
Melo Valls
M
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002051:Burkitt Lymphoma / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin
Linfomas no Hodgkin en la infancia. Valoración de resultados terapéuticos según criterios histopatológicos (GICOP).